News

Filter

Current filters:

Biogen IdecGenentech

1 to 9 of 94 results

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute

18-11-2011

A US District Court has entered final judgment in favor of UK pharma giant GlaxoSmithKline (LSE: GSK)…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceuticalRoche

Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint

31-01-2011

Swiss drug major Roche’s (ROG: VX) subsidiary Genentech and Biogen Idec (Nasdaq: BIIB) on Friday…

Biogen IdecBiotechnologyGenentechNorth AmericaOncologyPharmaceuticalRegulationResearchRituxanRocheTarceva

US FDA approves Genentech/Roche’s Herceptin for HER2-positive metastatic stomach cancer; Roche amends deal with Biogen

22-10-2010

US biotech giant Genentech, part of Swiss drug major Roche (ROG: VX), says the US Food and Drug Administration…

Biogen IdecGenentechHerceptinLicensingNorth AmericaocrelizumabOncologyPharmaceuticalRegulationRoche

Genentech and Biogen sue GlaxoSmithKline and Genmab over Arzerra patent

26-03-2010

US biotechnology giant Genentech, a wholly-owned subsidiary of Switzerland’s Roche, and Biogen Idec…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineOncologyPatentsPharmaceuticalRituxanRoche

1 to 9 of 94 results

COMPANY SPOTLIGHT

Menarini

Back to top